The global molecular diagnostics market size is expected to reach USD 17.97 billion by 2030, and expanding at a CAGR of 4.5% from 2024 to 2030, according to a recent study by Grand View Research, Inc. The contraction in the market will be due to the decline in demand for molecular testing for COVID-19. However, factors such as the rising geriatric population and increasing demand for technologies such as NGS is expected to drive market growth.
Molecular Diagnostics Market Report Highlights
- The reagents segment dominated the market and accounted for a share of 62.2% of the global revenue in 2023. It is expected to maintain its dominance throughout the forecast years owing to its wide application scope in research & clinical settings and increasing adoption of novel tests.
- The polymerase chain reaction technology segment accounted for the largest revenue share in 2023. This is attributed to its use in detecting COVID-19 and other infectious diseases.
- The infectious diseases segment accounted for the largest revenue share in 2023. The increased usage of molecular, particularly PCR tests, for diagnosing COVID-19 has increased the segment share significantly.
- The central laboratories segment dominated the industry in 2023 owing to high procedure volumes for COVID testing and other healthcare indications in central laboratories.
- North America dominated the market and accounted for a 39.3% share in 2023. This is attributed to the rising epidemiology of infectious as well as chronic diseases, thus, encouraging companies to introduce novel molecular diagnostic tests, thereby boosting market growth.
- Asia Pacific is anticipated to exhibit significant growth from 2024 to 2030 owing to increased market penetration, initiatives of local market players to increase the adoption of novel diagnostic technologies, and high unmet market needs.
For More Details or Sample Copy please visit link @: Molecular Diagnostics Market Report
Molecular diagnostics plays an important role in infectious disease testing as they can yield effective and fast results. Hence, the increasing prevalence of hospital-acquired infections & infectious diseases is projected to drive the market over the forecast period. Increasing incidence and awareness regarding genetic disorders is further anticipated to accelerate market growth. The miniaturization of three basic molecular assays-nanobiotechnology, biochips, and microfluidics are expected to increase the accuracy and specificity of diagnostic outcomes, and hence, increase the demand for molecular diagnostic products. These improvements are expected to enhance the availability of PoC molecular diagnostic tests to yield quick and effective test results.
Companies are expanding their product portfolios with the acquisition of smaller companies. For instance, in March 2021, Hologic announced the acquisition of Diagenode-a molecular diagnostic company with a wide range of PCR instruments, facilitating the detection of over 30 bacteria-for USD 159 million. Similarly, in April 2021, F. Hoffmann-La Roche Ltd. acquired GenMark Diagnostics, Inc. at a price of USD 24.05 per share in cash, and it holds around 82.89% of total shares of GenMark Diagnostics. GenMark Diagnostics, Inc. has proprietary technologies, such as eSensor XT-8 and ePlex, which can be utilized in developing tests for infectious diseases, including bloodstream infections.
Analysis By Product
The reagents segment expected to maintain its dominance throughout the forecast years owing to its wide application scope in research & clinical settings and increasing adoption of novel tests. The instruments segment growth driven by extensive use of instruments in different healthcare facilities to diagnose life-threatening diseases. Moreover, introduction of technologically advanced instruments is further supporting the segment growth.
Analysis By Application
The increased usage of molecular, particularly PCR tests, for diagnosing COVID-19 has increased the segment share significantly. Moreover, the increasing prevalence of infectious diseases across the globe is further increasing the demand for novel molecular diagnostic tests. Increasing collaboration activities between research institutes and market players to develop new diagnostic solutions for cancer is supporting the oncology segment growth. For instance, in October 2023, QIAGEN and Myriad Genetics collaborated to develop companion diagnostic tests based on PCR, dPCR, and NGS technology for cancer.
Gain deeper insights on the market and receive your free copy with TOC now @: https://www.grandviewresearch.com/industry-analysis/molecular-diagnostics-market/request/rs15
Analysis By Technology
The polymerase chain reaction technology segments growth attributed to its use in detecting COVID-19 and other infectious diseases. The increasing use of high-throughput PCR technology to detect infectious diseases and genetic or inherited conditions is expected to drive growth. Sequencing technology segment growth can be attributed to the rising penetration of technology in diagnostic applications, introduction of novel NGS tests, and favorable initiatives by key players.
Latest Market Trends and Developments
Market players are launching new molecular diagnostic tests and instruments to chase unmet needs and partnerships to share patented technologies to increase the geographical presence of their existing technologies. Companies are increasing investment in the research & development of novel products for different end-use applications. Moreover, emerging players are getting financial aid from government and non-government organizations, which is supporting novel product development for the detection of multiple targeted diseases.
List of major companies in the Molecular Diagnostics Market
- BD
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Abbott
- Agilent Technologies, Inc.
- Danaher
- Hologic Inc. (Gen Probe)
- Illumina, Inc.
- Grifols, S.A.
- QIAGEN
Segmented the global molecular diagnostics market report based on product, technology, application, test location, and region:
For Customized reports or Special Pricing please visit @: https://www.grandviewresearch.com/checkout/select-license/molecular-diagnostics-market
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Product
1.2.2. Technology
1.2.3. Application
1.2.4. Test Location
1.3. Regional Scope
1.4. Estimates and Forecast Timeline
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.7. Details of primary research
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity flow analysis (Model 1)
1.9.1.1. Approach 1: Commodity flow approach
1.9.2. Volume price analysis (Model 2)
1.9.2.1. Approach 2: Volume price analysis
1.10. Research Scope and Assumptions
1.10.1. List of Secondary Sources
1.10.2. List of Primary Sources
1.10.3. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Molecular Diagnostics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Increase in geriatric population
3.2.1.2. Introduction of technologically advanced products
3.2.1.3. Increase in demand for point-of-care Testing
3.2.1.4. Growing prevalence of target diseases
3.2.1.5. Increasing external funding for R&D
3.2.2. Market Restraints Analysis
3.2.2.1. Presence of ambiguous regulatory framework
3.2.2.2. High prices of molecular diagnostics tests
3.3. Molecular Diagnostics Market Analysis Tools
3.3.1. Porter’s Analysis
3.3.1.1. Bargaining power of the suppliers
3.3.1.2. Bargaining power of the buyers
3.3.1.3. Threats of substitution
3.3.1.4. Threats from new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic and Social landscape
3.3.2.3. Technological landscape
3.3.2.4. Legal landscape
3.4. Market Opportunity Analysis
3.5. CLIA-Waived Tests and Instruments
3.6. Pricing Analysis
Chapter 4. Molecular Diagnostics Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Molecular Diagnostics Market: Product Movement Analysis, USD Million, 2023 & 2030 (Volume Analysis)
4.3. Instruments
4.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million) (Volume, Number of Instruments Sold)
4.4. Reagents
4.4.1. Reagents Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million) (Volume, Number of Tests Sold)
4.5. Software
4.5.1. Software Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 5. Molecular Diagnostics Market: Technology Estimates & Trend Analysis
5.1. Technology Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Molecular Diagnostics Market by Technology Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Polymerase chain reaction (PCR)
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2. PCR, by Type
5.4.1.2.1. Multiplex PCR
5.4.1.2.1.1. Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
5.4.1.2.2. Other PCR
5.4.1.2.2.1. Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
5.4.1.3. PCR, by Product
5.4.1.3.1. Instruments
5.4.1.3.1.1. Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million) (Volume, Number of Instruments Sold)
5.4.1.3.2. Reagents
5.4.1.3.2.1. Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million) (Volume, Number of Tests Sold)
5.4.1.3.3. Others
5.4.1.3.3.1. Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
5.4.2. In Situ Hybridization (ISH)
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.2. Instruments
5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) (Volume, Number of Instruments Sold)
5.4.2.3. Reagents
5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million) (Volume, Number of Tests Sold)
5.4.2.4. Others
5.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Isothermal Nucleic Acid Amplification Technology (INAAT)
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3.2. Instruments
5.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) (Volume, Number of Instruments Sold)
5.4.3.3. Reagents
5.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million) (Volume, Number of Tests Sold)
5.4.3.4. Others
5.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Chips and Microarrays
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4.2. Instruments
5.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) (Volume, Number of Instruments Sold)
5.4.4.3. Reagents
5.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million) (Volume, Number of Tests Sold)
5.4.4.4. Others
5.4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.5. Mass Spectrometry
5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.5.2. Instruments
5.4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) (Volume, Number of Instruments Sold)
5.4.5.3. Reagents
5.4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million) (Volume, Number of Tests Sold)
5.4.5.4. Others
5.4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.6. Sequencing
5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.6.2. Instruments
5.4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) (Volume, Number of Instruments Sold)
5.4.6.3. Reagents
5.4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million) (Volume, Number of Tests Sold)
5.4.6.4. Others
5.4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.7. Transcription Mediated Amplification (TMA)
5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.7.2. Instruments
5.4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) (Volume, Number of Instruments Sold)
5.4.7.3. Reagents
5.4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million) (Volume, Number of Tests Sold)
5.4.7.4. Others
5.4.7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.8. Others
5.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.8.2. Instruments
5.4.8.2.1. Market estimates and forecasts 2018 to 2030 (USD Million) (Volume, Number of Instruments Sold)
5.4.8.3. Reagents
5.4.8.3.1. Market estimates and forecasts 2018 to 2030 (USD Million) (Volume, Number of Tests Sold)
5.4.8.4. Services
5.4.8.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Molecular Diagnostics Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Molecular Diagnostics Market: Application Movement Analysis, USD Million, 2023 & 2030
6.3. Oncology
6.3.1. Oncology Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.2. Breast Cancer
6.3.2.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.3. Prostate Cancer
6.3.3.1. Prostate Cancer Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.4. Colorectal Cancer
6.3.4.1. Colorectal Cancer Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.5. Cervical Cancer
6.3.5.1. Cervical Cancer Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.6. Kidney Cancer
6.3.6.1. Kidney Cancer Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.7. Liver Cancer
6.3.7.1. Liver Cancer Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.8. Blood Cancer
6.3.8.1. Blood Cancer Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.9. Lung Cancer
6.3.9.1. Lung Cancer Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3.10. Other Cancer
6.3.10.1. Other Cancer Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.4. Pharmacogenomics
6.4.1. Pharmacogenomics Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5. Infectious Diseases
6.5.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
6.5.2.1. Methicillin-resistant Staphylococcus Aureus (MRSA) Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.3. Clostridium Difficile
6.5.3.1. Clostridium Difficile Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.4. Vancomycin-resistant Enterococci (VRE)
6.5.4.1. Vancomycin-resistant Enterococci (VRE) Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.5. Carbapenem-resistant Bacteria
6.5.5.1. Carbapenem-resistant Bacteria Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.6. Flu
6.5.6.1. Flu Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.7. Respiratory Syncytial Virus (RSV)
6.5.7.1. Respiratory Syncytial Virus (RSV) Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.8. Candida
6.5.8.1. Candida Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.9. Tuberculosis and Drug-resistant TBA
6.5.9.1. Tuberculosis and Drug-resistant TBA Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.10. Meningitis
6.5.10.1. Meningitis Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.11. Gastrointestinal Panel Testing
6.5.11.1. Gastrointestinal Panel Testing Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.12. Chlamydia
6.5.12.1. Chlamydia Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.13. Gonorrhea
6.5.13.1. Gonorrhea Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.14. HIV
6.5.14.1. HIV Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.15. Hepatitis C
6.5.15.1. Hepatitis C Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.16. Hepatitis B
6.5.16.1. Hepatitis B Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5.17. Other Infectious Disease
6.5.17.1. Other Infectious Disease Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6. Genetic Testing
6.6.1. Genetic Testing Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.2. Newborn Screening
6.6.2.1. Newborn Screening Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.3. Predictive and Presymptomatic Testing
6.6.3.1. Predictive and Presymptomatic Testing Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.4. Other Genetic Testing
6.6.4.1. Other Genetic Testing Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.7. Neurological Disease
6.7.1. Neurological Disease Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.8. Cardiovascular Disease
6.8.1. Cardiovascular Disease Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.9. Microbiology
6.9.1. Microbiology Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.10. Others
6.10.1. Others Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 7. Molecular Diagnostics Market: Test Location Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Molecular Diagnostics Market: Test Location Movement Analysis, USD Million, 2023 & 2030
7.3. Point of Care
7.3.1. Point of Care Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4. Central Laboratories
7.4.1. Central Laboratories Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5. Self-Test or OTC
7.5.1. Self-Test or OTC Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
MolecularDiagnostics #PrecisionMedicine #HealthcareInnovation #GenomicTesting #DiagnosticsTechnology #Biotechnology #PersonalizedMedicine #DiagnosticRevolution #NGS (Next-Generation Sequencing) #BiomarkerDiscovery #InfectiousDiseaseDiagnosis #CancerDetection #Theranostics #Bioinformatics #MolecularBiology #DiagnosticTrends #MedicalTechnology #LaboratoryTesting #PointofCareDiagnostics #HealthTechInnovation
In-depth Market Study 